Oxaliplatin and Leucovorin Plus Fluorouracil Versus Irinotecan and Leucovorin Plus Fluorouracil Combination Chemotherapy as a First-line Treatment in Patients with Metastatic or Recurred Gastric Adenocarcinoma.
- Author:
Sun Hyung KANG
1
;
Jeong Il KIM
;
Hee Seok MOON
;
Seok Hyun KIM
;
Jae Kyu SUNG
;
Byung Seok LEE
;
Hyun Yong JEONG
Author Information
- Publication Type:Original Article ; English Abstract
- Keywords: Gastric adenocarcinoma; Oxaliplatin; Irinotecan
- MeSH: Adenocarcinoma/*drug therapy/mortality/secondary; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols/*therapeutic use; Camptothecin/analogs & derivatives/therapeutic use; Female; Fluorouracil/therapeutic use; Humans; Leucovorin/therapeutic use; Male; Middle Aged; Neoplasm Recurrence, Local/drug therapy; Organoplatinum Compounds/therapeutic use; Recurrence; Retrospective Studies; Stomach Neoplasms/*drug therapy/mortality; Survival Analysis
- From:The Korean Journal of Gastroenterology 2010;55(1):26-32
- CountryRepublic of Korea
- Language:Korean
- Abstract: BACKGROUND/AIMS: We performed retrospective study in order to compare oxaliplatin, leucovorin, and fluorouracil (FOLFOX) versus irinotecan, leucovorin, and fluorouracil (FOLFIRI) in recurred or metastatic gastric adenocarcinoma. METHODS: We investigated 56 patients who were diagnosed with recurred or metastatic gastric adenocarcinoma in a single center during march, 2003 to march, 2008. The patients received either FOLFOX or FOLFIRI chemotherapy. RESULTS: There were no significant difference between the Oxaliplatin group (30 patients) and Irinotecan group (26 patients) in sex, age, and ECOG performance (p>0.05). Oxaliplatin group showed 1 case of CR (3.3%) and 12 cases of PR (40%), making the response rate 43.3%. Irinotecan group showed CR in 2 cases (7.7%) and PR in 10 cases (38.5%), making the response rate 46.2%. The median value of time to progression was 4 months in the oxlaplatin group and 4.5 months in the irinotecan group. The overall survival showed no significant difference (p=0.784), with the irinotecan group (9.7 months) being slightly longer than the Oxaliplatin group (8.3 months). Grade 3/4 neutropenia occurred similarly in both groups (4 cases in the oxalplatin group, 9 in the irinotecan group). CONCLUSIONS: Both combination treatment can be used safely and effectively in recurred or metastatic gastric adenocarcinoma.
